Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On November 20, 2026,
Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing updated results from its ongoing Phase 1 ACESOT-1051
trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. A copy of the press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
In addition, on November
20, 2026, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit
99.2 hereto and incorporated herein by reference.
(d) Exhibits.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Exhibit 99.1

Aprea Therapeutics
Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors
(ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Safety profile
to date with continuous daily dosing supports continued dose optimization and clinical development
Pharmacodynamic
data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration
Planned expansion
into focused cohorts in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, where WEE1 inhibition
may be most therapeutically relevant
DOYLESTOWN, PA, November 20, 2026
(GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage
precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
cancers, today announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective
WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets
and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center,
the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels.
The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response
in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic
evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported
clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients
with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill
expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of
2027.
Updated ACESOT-1051 findings
The presentation, “Interim Results
From the First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051),” includes
the following findings:
| · | Clinical
activity and durability: Out of the 56 patients who enrolled in this dose escalation
trial (including those patients treated at doses believed to be subtherapeutic), 43 are evaluable
for response. Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial
responses, one confirmed and one unconfirmed. The confirmed response, in a patient with uterine
carcinosarcoma treated at 220 mg, was ongoing with treatment beyond 10 months at the time
of data cutoff. Sixteen patients had a best overall response of stable disease, five of which
had a duration of 4 months or longer. Thirteen patients were still awaiting their initial
on-treatment imaging studies at the time of data cutoff. |
| · | WEE1
target engagement: Pharmacodynamic data (PD) from paired skin punch biopsies were stained
by IHC for phosphorylation of CDK1-Y15, an established PD marker of WEE1 target engagement.
Reductions of at least 50% in pCDK1-Y15 from baseline were observed in 21 of 25 evaluable
patients (84%) across multiple dose levels. |

| · | Initial
Safety and tolerability: One dose-limiting toxicity (DLT) was observed among 56 treated
patients. The DLT was elevation of AST and ALT without elevation in bilirubin in blood tests
in a patient with known liver metastases treated at the 50 mg dose level. Grade 3/4 neutrophil
count decrease was reported in 4 patients (7%) (1 Grade 3, 3 Grade 4, one of which was serious)
all at the 300 mg dose level, with no reported cases of febrile neutropenia. Two patients
(4%) experienced Grade 3 pneumonitis, both reported as serious. Other Grade ≥3 treatment-related
adverse events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea
(2%). The most common all grade treatment-related adverse events were nausea (41%), fatigue
(25%), diarrhea (14%) and vomiting (14%). |
| · | Pharmacokinetics:
APR-1051 exposure increased with once-daily dosing through 300 mg, with an approximately
18-hour median half-life supporting once-daily dosing. Dose escalation has been modified
to include 250 mg and 350 mg dose levels, and Part 1 now provides for up to 110 patients;
previously disclosed dose levels of 400 mg and 500 mg are under evaluation. |
“These interim results reinforce
our focus on advancing APR-1051 in biomarker selected cancers,” said Oren Gilad, Ph.D., President and Chief Executive Officer of
Aprea. “The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed
in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target
engagement and pharmacokinetics compatible with continuous once-daily dosing. Our strategy is to transition from a broad, biomarker-enriched
Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051. Our goal is to evaluate
whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet
medical need.”
Expanded enrollment focused on biologically
selected cancers
Aprea is refining enrollment to evaluate
APR-1051 in populations that may be particularly sensitive to WEE1 inhibition. The Company is working with a diagnostics partner to develop
an immunohistochemistry (IHC) assay for cyclin E overexpression, to support patient identification and enrollment of patients with cyclin
E-overexpressing PROC. The Company is also expanding the trial to more than 10 clinical sites, from the nine active sites previously
disclosed. This effort complements continued evaluation of tumors with CCNE1, CCNE2 or FBXW7 alterations, while an emerging clinical
activity signal in PPP2R1A-mutated uterine cancers provides an additional area for evaluation as enrollment expands.
“Patients with advanced uterine
and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies,” said Eugene
Kennedy, MD, Chief Medical Advisor at Aprea. “The observed target engagement and prolonged treatment duration in a patient with
a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients. Expanding enrollment in biologically
selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability.
These data will be important for optimizing dose selection and informing subsequent development.”
ACESOT-1051 Trial Design
ACESOT-1051 is a multicenter, open-label
Phase 1 study evaluating oral, single-agent APR-1051 administered once daily in 28-day cycles. Part 1 includes dose escalation and
backfill expansion of up to 110 patients, using accelerated titration at lower dose levels followed by a Bayesian optimal interval (BOIN)
design. Backfill enrollment allows additional patients to be evaluated at dose levels that have cleared safety review. Part 2 is
a dose selection optimization stage of up to 80 patients, who will be randomized 1:1 to two selected doses to determine the recommended
Phase 2 dose (RP2D).

The primary objectives are to characterize
safety and dose-limiting toxicities, determine the maximum tolerated or maximum administered dose, and establish the RP2D. Secondary
objectives include pharmacokinetics and preliminary antitumor activity assessed using Response Evaluation Criteria in Solid Tumors (RECIST)
or Prostate Cancer Working Group 3 (PCWG3) criteria, as applicable.
For more information on ACESOT-1051,
refer to ClinicalTrials.gov identifier NCT06260514.
About APR-1051
APR-1051 is an investigational, orally
bioavailable, selective small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond
to DNA damage. APR-1051 was designed to minimize off-target inhibition of the PLK family of kinases, with the goal of improving its therapeutic
profile. Its potential differentiation remains under clinical evaluation.
About Aprea
Aprea is a clinical-stage
precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
cancers. The Company is pursuing an approach to treating cancer that seeks to exploit vulnerabilities associated with cancer cell mutations.
This approach is designed to kill tumor cells while minimizing the effect on normal, healthy cells. Aprea believes its technology has
potential applications across multiple cancer types, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma.
The Company’s lead program is APR-1051, an oral, small molecule inhibitor of WEE1 kinase, currently in a Phase 1 clinical trial.
The Company’s second clinical-stage product candidate, ATRN-119, is a small molecule ATR inhibitor for which the Company has completed
a Phase 1 dose-escalation study and is exploring combination approaches. For more information, please visit the Company’s website
at www.aprea.com.
The Company may
use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information
and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
Certain information
contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation
Reform Act of 1995, related to our study analyses, clinical trials, regulatory submissions, development plans and projected cash position.
We may, in some cases, use terms such as “future,” “predicts,” “believes,” “potential,”
“continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,”
“targeting,” “confidence,” “may,” “could,” “might,” “likely,”
“will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently
available to management, and involve risks, potential changes in circumstances, assumptions and uncertainties. All statements contained
in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability
to develop, commercialize and achieve market acceptance of our current and planned product candidates, our research and development efforts,
including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial
position, projected cash runway, plans and objectives for future operations, the timing, progress, enrollment and completion of our ongoing
and planned clinical trials, the timing of expected clinical data updates and medical meeting presentations, the potential expansion
of ACESOT-1051, the planned addition of clinical sites and dose levels, the development of a companion IHC assay, the potential development
of APR-1051 in single-agent and combination settings, the potential further development of ATRN-119, the scope and duration of our intellectual
property protection, and the potential advancement of our early-stage programs. Any or all of the forward-looking statements may turn
out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking
statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our
ongoing and anticipated clinical trials for our current product candidates, including the timing of initiation, pace of enrollment and
completion of trials, our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected
expenses, our need for substantial additional funding, which may not be available on acceptable terms or at all, the receipt and timing
of interim or preliminary results, which are not necessarily indicative of final results and have not been fully source verified, the
occurrence of serious or unexpected adverse events, including pneumonitis and neutropenia, that may require dose modifications or affect
further development, our understanding of product candidate mechanisms of action and interpretation of preclinical and early clinical
results from our clinical development programs, our ability to predict clinical outcomes based on such preclinical and early clinical
results, our ability to successfully develop and validate a diagnostic assay with third parties, the timing and outcome of regulatory
interactions, our ability to regain and maintain compliance with The Nasdaq Stock Market continued listing requirements, and the other
risks, uncertainties and factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For
all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking
statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Sean Naughton Ph.D.
Russo Partners, LLC
sean.naughton@russopartnersllc.com